AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

AstraZeneca AZN reported positive top-line results from a late-stage study evaluating the safety, tolerability and efficacy ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its ...

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

AstraZeneca Plc’s experimental hypertension drug Baxdrostat reduced the blood pressure of patients who have an uncontrolled ...

Astra said its experimental drug Baxdrostat reduced the blood pressure of patients who have a treatment-resistant form of ...

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial, indicating that the highly selective aldosterone synthase inhibitor (ASI), baxdrostat, significantly lowered the mean seated ...

AstraZeneca's baxdrostat demonstrated significant blood pressure reduction in a late-stage trial for treatment-resistant ...